---
aliases: [BMY, BMS, Bristol-Myers]
---
#actor #pharma #oncology #immunology #usa #public

**Bristol-Myers Squibb** — Opdivo, Eliquis. Multiple patent cliffs. Restructuring mode. CAR-T leader.

---

## Why BMS matters

| Metric | Value |
|--------|-------|
| Ticker | BMY (NYSE) |
| Revenue | ~$46B |
| Key drugs | Opdivo, Eliquis, Revlimid |
| Patent cliffs | 2026-2028 |

---

## Key products

| Product | Category | Status |
|---------|----------|--------|
| **Eliquis** | Blood thinner | $12B+, LOE 2026 |
| **Opdivo** | Oncology (I-O) | $9B+, LOE 2028 |
| **Revlimid** | Oncology | LOE ongoing |
| CAR-T (Breyanzi, Abecma) | Cell therapy | Growing |

---

## Patent cliff pressure

| Drug | Expiry | Revenue at risk |
|------|--------|-----------------|
| Eliquis | 2026 | ~$12B |
| Opdivo | 2028 | ~$9B |
| Revlimid | Ongoing | ~$6B |

**Challenge:** ~60% of revenue facing LOE by 2028.

---

## Growth assets

| Product | Category | Trend |
|---------|----------|-------|
| Reblozyl | Anemia | Growing |
| Breyanzi | CAR-T | Expanding |
| Camzyos | Cardio | Ramping |
| Sotyktu | Dermatology | Launching |

---

## Restructuring

| Action | Detail |
|--------|--------|
| Cost cuts | Multi-billion savings program |
| Workforce | Reductions ongoing |
| Focus | Prioritize growth assets |

---

## Cell therapy leadership

| Product | Indication |
|---------|------------|
| Breyanzi | Lymphoma |
| Abecma | Multiple myeloma |

**Position:** Leading CAR-T portfolio, but competitive.

---

## Investment case

**Bull:**
- CAR-T leadership
- Growth assets ramping
- Beaten-down valuation
- Restructuring benefits

**Bear:**
- Massive patent cliffs
- Eliquis generics 2026
- Execution risk
- Competition in CAR-T

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | BMY |
| Exchange | NYSE |
| Revenue | ~$46B |
| Focus | Oncology, immunology |

---

## Related

- [[Merck]] — I-O competitor
- [[Biopharma]] — sector

---

## Sources

- [BMS investor relations](https://www.bms.com/investors.html)

*Created 2026-01-09*
